Matinas Biopharma Holdings Total Revenue

Matinas Biopharma Holdings (MTNB) currently reports a total revenue of $0 as of June 2026. That compares with $960K in the prior-year period — down 100.0% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Matinas Biopharma Holdings's total revenue history and peer comparisons.

Matinas Biopharma Holdings's total revenue decreased from $960K to $0 — a 100.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Matinas Biopharma Holdings's total revenue of $0 is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Matinas Biopharma Holdings reported $0 in total revenue as of June 2026. That compares with $960K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total revenue of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Matinas Biopharma Holdings, and consider following MTNB for alerts when major investors trade the stock.